A
Ana de Vera
Researcher at Novartis
Publications - 14
Citations - 2473
Ana de Vera is an academic researcher from Novartis. The author has contributed to research in topics: Fingolimod & Population. The author has an hindex of 8, co-authored 14 publications receiving 2244 citations.
Papers
More filters
Journal ArticleDOI
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
Jeffrey A. Cohen,Frederik Barkhof,Giancarlo Comi,Hans Peter Hartung,Bhupendra Khatri,Xavier Montalban,Jean Pelletier,Ruggero Capra,Paolo Gallo,Guillermo Izquierdo,Klaus Tiel-Wilck,Ana de Vera,James Jin,Tracy Stites,Stacy Wu,Shreeram Aradhye,Ludwig Kappos +16 more
TL;DR: This trial showed the superior efficacy of oral fingolimod with respect to relapse rates and MRI outcomes in patients with multiple sclerosis, as compared with intramuscular interferon beta-1a.
Journal ArticleDOI
Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings
Ludwig Kappos,Jeffrey A. Cohen,William Collins,Ana de Vera,Lixin Zhang-Auberson,Shannon Ritter,Philipp von Rosenstiel,Gordon Francis +7 more
TL;DR: The safety profile of fingolimod has been well characterized in this large combined trial population, and although infrequent SAEs can occur, there is no increased risk of infections, malignancies or serious cardiovascular events versus placebo.
Journal ArticleDOI
Impact of Fingolimod Therapy on Magnetic Resonance Imaging Outcomes in Patients With Multiple Sclerosis
Ernst-Wilhelm Radue,Paul O'Connor,Chris H. Polman,Reinhard Hohlfeld,Peter A. Calabresi,Krystof Selmaj,Nicole Mueller-Lenke,Catherine Agoropoulou,Frederick Holdbrook,Ana de Vera,Lixin Zhang-Auberson,Gordon Francis,Pascale Burtin,Ludwig Kappos +13 more
TL;DR: Fingolimod therapy resulted in rapid and sustained reductions in inflammatory lesion activity as assessed by gadolinium-enhancing and new/newly enlarged T2 lesions after 6, 12, and 24 months of therapy.
Journal ArticleDOI
Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial
Michael G. Hanna,Umesh A. Badrising,Olivier Benveniste,Thomas E. Lloyd,Merrilee Needham,Hector Chinoy,Masashi Aoki,Pedro Machado,Christina Liang,Katrina Reardon,Marianne de Visser,Dana P. Ascherman,Richard J. Barohn,Mazen M. Dimachkie,James Miller,John T. Kissel,Bjorn Oskarsson,Nanette C. Joyce,P. Van den Bergh,Jonathan Baets,J. De Bleecker,Chafic Karam,William S. David,Massimiliano Mirabella,Sharon P. Nations,Hans H. Jung,Elena Pegoraro,Lorenzo Maggi,Carmelo Rodolico,Massimiliano Filosto,Aziz Shaibani,Kumaraswamy Sivakumar,Namita Goyal,Madoka Mori-Yoshimura,Satoshi Yamashita,Naoki Suzuki,Masahisa Katsuno,Ken-ya Murata,Hiroyuki Nodera,Ichizo Nishino,Carla D. Romano,Valerie S.L. Williams,John Vissing,Lixin Zhang Auberson,Min Wu,Ana de Vera,Dimitris Papanicolaou,Anthony A. Amato +47 more
TL;DR: The safety, efficacy, and tolerability of bimagrumab-a fully human monoclonal antibody-in individuals with inclusion body myositis were assessed and no significant adverse cardiac effects were recorded on electrocardiography or echocardiography.
Journal ArticleDOI
Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)
Jerry Bagel,John K Nia,Peter W Hashim,Manmath Patekar,Ana de Vera,Sophie Hugot,Kuan Sheng,Summer Xia,Isabelle Gilloteau,Elisa Muscianisi,Andrew Blauvelt,Mark Lebwohl +11 more
TL;DR: The results of this study confirm the superior efficacy of secuk inumab over ustekinumab in treating patients with moderate to severe psoriasis.